BNF:

Not listed

Status:

Do Not Prescribe (DNP), Red

Decision Date:

December 2017

Comments

RED^1,2,3: NICE TA485 - Sarilumab for moderate to severe rheumatoid arthritis. (Decision date - December 2017)

CCG commissioned drug.

 DNP: NICE TA1104 (terminated appraisal) Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (Decision date Nov 2025)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again